Analysis of lung cancer diagnosis and management in clinical practice
Official title: Landsteiner Lung Cancer Research Platform (LALUCA) A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice
Run by Karl Landsteiner Institute for Lung Research and Pneumological Oncology · NCT04733430 · Data updated 2026-11-12
This study is trying to see how lung cancer is diagnosed and treated in everyday medical settings to improve care by focusing on genetic testing and treatment options for patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 125 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Karl Landsteiner Institute for Lung Research and Pneumological Oncology Academic / other |
| Locations | 1 site (Vienna) |
| Status | Recruiting |
| Started | April 17, 2020 |
| Main results expected | April 2030 |
| Study ends | April 2030 |
| Registry record updated | March 18, 2024 |
| Trial ID | NCT04733430 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with histologically confirmed lung cancer who can provide informed consent.
✕Probably not a fit
Patients without a confirmed diagnosis of lung cancer or those unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project involves a prospective analysis of lung cancer diagnosis and treatment in real-world settings. It aims to establish a clinical platform for collecting data on molecular testing, treatment sequences, and disease progression in lung cancer patients. A key focus is on molecular biomarker testing and next-generation sequencing (NGS) to identify druggable mutations that can improve patient outcomes. The collected data will help assess the current state of lung cancer care and identify areas for improvement.
Why it matters
Potential benefit: If successful, this project could enhance the quality of care and treatment outcomes for lung cancer patients by providing insights into effective diagnostic and therapeutic strategies.
How similar studies have gone: Other studies focusing on molecular testing and NGS in lung cancer have shown promising results, indicating that this approach is supported by previous successful research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed consent * Histologically confirmed lung cancer * Age ≥ 18 years * Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments Exclusion Criteria: \-
Where it's running
-
Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie
Vienna, Austria Recruiting
Study contacts
- Principal investigator: Georg-Christian Funk, MD — 2nd Medical Department with Pneumology
- Study coordinator: Georg-Christian Funk, MD
- Email: georg-christian.funk@gesundheitsverbund.at
- Phone: +43 1 4000-2203
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.